Shifting the focus - the primary role of IL-23 in psoriasis and other inflammatory disorders

The role of IL 23 in the treatment of psoriasis

(2017) Lluís Puig   Expert Review of Clinical Immunology

Efficacy and Safety of MEDI2070, an Antibody Against Interleukin 23, in Patients With Moderate to Severe Crohn’s Disease: A Phase 2a Study

(2017) Bruce E. Sands et al.   GASTROENTEROLOGY

Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

(2017) Andrew Blauvelt et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator–controlled VOYAGE 2 trial

(2017) Kristian Reich et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials

(2017) Kristian Reich et al.   LANCET

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

(2017) Brian G Feagan et al.   LANCET

Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis

(2017) Kim A. Papp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Secukinumab for Long-Term Treatment of Psoriatic Arthritis: A Two-Year Followup From a Phase III, Randomized, Double-Blind Placebo-Controlled Study

(2017) Arthur Kavanaugh et al.   ARTHRITIS CARE & RESEARCH

Secukinumab in Active Rheumatoid Arthritis: A Phase III Randomized, Double-Blind, Active Comparator- and Placebo-Controlled Study

(2017) Francisco J. Blanco et al.   Arthritis & Rheumatology

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Brodalumab in Patients With Moderate-to-Severe Crohn’s Disease

(2016) Stephan R Targan et al.   AMERICAN JOURNAL OF GASTROENTEROLOGY

Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1

(2016) Philip J Mease et al.   ANNALS OF THE RHEUMATIC DISEASES

Therapeutic Targeting of IL-17 and IL-23 Cytokines in Immune-Mediated Diseases

(2016) George E. Fragoulis et al.   Annual Review of Medicine

A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis

(2016) K.A. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

No meaningful association between suicidal behavior and the use of IL-17A-neutralizing or IL-17RA-blocking agents

(2016) Andrea Chiricozzi et al.   Expert Opinion On Drug Safety

Secukinumab long-term safety experience: A pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis

(2016) Peter C.M. van de Kerkhof et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis

(2016) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab in treatment of Crohn’s disease: design, development, and potential place in therapy

(2016) Parakkal Deepak et al.   Drug Design Development and Therapy

Interleukin-23-Dependent γ/δ T Cells Produce Interleukin-17 and Accumulate in the Enthesis, Aortic Valve, and Ciliary Body in Mice

(2016) Annika Reinhardt et al.   Arthritis & Rheumatology

Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial

(2015) K. Papp et al.   BRITISH JOURNAL OF DERMATOLOGY

Interleukin-23-Independent IL-17 Production Regulates Intestinal Epithelial Permeability

(2015) Jacob S. Lee et al.   IMMUNITY

Gut-Busters: IL-17 Ain’t Afraid of No IL-23

(2015) Natasha Whibley et al.   IMMUNITY

Differential Roles for Interleukin-23 and Interleukin-17 in Intestinal Immunoregulation

(2015) Joseph R. Maxwell et al.   IMMUNITY

Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial

(2015) James G. Krueger et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

CD11c+ monocyte/macrophages promote chronic Helicobacter hepaticus-induced intestinal inflammation through the production of IL-23

(2015) I C Arnold et al.   Mucosal Immunology

Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis

(2015) Dominique Baeten et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis

(2015) Kenneth B. Gordon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ustekinumab for the treatment of patients with active ankylosing spondylitis: results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)

(2014) Denis Poddubnyy et al.   ANNALS OF THE RHEUMATIC DISEASES

Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis

(2014) Howard Sofen et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

IL-23 Promotes Maintenance but Not Commitment to the Th17 Lineage

(2014) G. L. Stritesky et al.   JOURNAL OF IMMUNOLOGY

Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis

(2014) E. Guttman-Yassky et al.   JOURNAL OF IMMUNOLOGY

Epidermal Th22 and Tc17 Cells Form a Localized Disease Memory in Clinically Healed Psoriasis

(2014) S. Cheuk et al.   JOURNAL OF IMMUNOLOGY

IL-23 from Langerhans Cells Is Required for the Development of Imiquimod-Induced Psoriasis-Like Dermatitis by Induction of IL-17A-Producing γδ T Cells

(2014) Ryutaro Yoshiki et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Interleukin 17A: Toward a new understanding of psoriasis pathogenesis

(2014) Charles W. Lynde et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials

(2014) Richard G. Langley et al.   NEW ENGLAND JOURNAL OF MEDICINE

Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS

(2014) I. Essers et al.   RHEUMATOLOGY

Paradoxical effects of anti-TNF-α agents in inflammatory diseases

(2013) Daniel Wendling et al.   Expert Review of Clinical Immunology

Specific targeting of interleukin-23p19 as effective treatment for psoriasis

(2013) Adriane A. Levin et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Langerinneg conventional dendritic cells produce IL-23 to drive psoriatic plaque formation in mice

(2013) C. Wohn et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial

(2012) Wolfgang Hueber et al.   GUT

Therapeutic potential of targeting IL-17

(2012) Sarah A Jones et al.   NATURE IMMUNOLOGY

IL-23 induces spondyloarthropathy by acting on ROR-γt+ CD3+CD4−CD8− entheseal resident T cells

(2012) Jonathan P Sherlock et al.   NATURE MEDICINE

Briakinumab for the Treatment of Plaque Psoriasis

(2011) Pawel Traczewski et al.   BIODRUGS

Efficacy and safety results from a phase III, randomized controlled trial comparing the safety and efficacy of briakinumab with etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) B.E. Strober et al.   BRITISH JOURNAL OF DERMATOLOGY

Efficacy and safety of briakinumab vs. etanercept and placebo in patients with moderate to severe chronic plaque psoriasis

(2011) A.B. Gottlieb et al.   BRITISH JOURNAL OF DERMATOLOGY

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Human TH17 Cells Are Long-Lived Effector Memory Cells

(2011) I. Kryczek et al.   Science Translational Medicine

Elevated tumour necrosis factor-alpha (TNF-α) biological activity in psoriatic skin lesions

(2010) P. ETTEHADI et al.   CLINICAL AND EXPERIMENTAL IMMUNOLOGY

IL-23-Mediated Psoriasis-Like Epidermal Hyperplasia Is Dependent on IL-17A

(2010) H. L. Rizzo et al.   JOURNAL OF IMMUNOLOGY

Psoriasis: what we have learned from mouse models

(2010) Erwin F. Wagner et al.   Nature Reviews Rheumatology

Psoriatic Skin Lesions Induced by Tumor Necrosis Factor Antagonist Therapy: Clinical Features and Possible Immunopathogenesis

(2010) Angelique N. Collamer et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice Is Mediated via the IL-23/IL-17 Axis

(2009) L. van der Fits et al.   JOURNAL OF IMMUNOLOGY

Association of interleukin-23 receptor variants with ankylosing spondylitis

(2008) Proton Rahman et al.   ARTHRITIS AND RHEUMATISM

Polymorphisms of the IL12B and IL23R Genes Are Associated with Psoriasis

(2008) Rajan P. Nair et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

(2008) Craig L Leonardi et al.   LANCET

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

(2008) Kim A Papp et al.   LANCET

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

(2008) Benjamin M Segal et al.   LANCET NEUROLOGY